Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
Ann Neurol 92:201-212, Lindgren, U.,et al, 2022
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies
Medicine 92:15-24, Fernandez, C.,et al, 2013
The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
Medicine 92:223-243, Rider, L.,et al, 2013
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Juvenile Dermatomyositis and Other Idiopathic Inflammatory Myopathies of Childhood
Lancet 371:2201-2212, Feldman,B.M.,et al., 2008
Polymyositis and Dermatomyositis
Lancet 362:971-982, Dalakas,M.C.&Hohlfeld,R., 2003
Paraneoplastic Syndromes Involving the Nervous System
NEJM 349:1543-1554, Darnell,R.B. &Posner,J.B., 2003
Necrotizing Myopathy with Pipestem Capillaries, Microvasc Depos
Neurol 41:936-939, Emslie-Smith,A.M.&Engel,A.G., 1991
Current Concepts in the Idiopathic Inflammatory Myopathies:Polymyositis, Dermatomyositis, and Related Disorders
Ann Int Med 111:143-157, Plotz,P.H.,et al, 1989
Eosinophilic Polymyositis
Ann Neurol 1:65, Layzer,R.B.,et al, 1977
Polymyositis & Dermatomyositis
NEJM 292:344, 1975, 292:403975., Bohan,A.,et al, 1975